심장 동종이식편 혈관병증에 대한 심장 재이식 1예
Heart Retransplantation to Treat a Case of Refractory Cardiac Allograft Vasculopathy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
.
Abstract
Cardiac allograft vasculopathy is one of the most important causes of poor long-term survival after heart transplantation. The condition tends to be diffuse, usually affecting the mid-to-distal portions of the coronary artery. Reperfusion therapy is ineffective. Everolimus, an inhibitor of proliferation signaling, has been reported to prevent development of the condition; however, the efficacy thereof has not yet been fully accepted. The only definitive treatment for cardiac allograft vasculopathy is retransplantation. Herein, we describe the case of a 15-year-old boy who underwent heart retransplantation because of rapidly progressive cardiac allograft vasculopathy.
참고문헌 (10)
- Lund LH, "The registry of the International Society for Heart and Lung Transplantation : thirty-first official adult heart transplant report--2014; focus theme : retransplantation", J Heart Lung Transplant, 33, pp.996~1008 (2014)
- Avery RK, "Cardiac-allograft vasculopathy", N Engl J Med, 349, pp.829~830 (2003)
- Mehra MR, "International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010", J Heart Lung Transplant, 29, pp.717~727 (2010)
- Costanzo MR, "Heart transplant coronary artery disease detected by coronary angiography :a multiinstitutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database", J Heart Lung Transplant, 17, pp.744~753 (1998)
- Pollack A, "Detection and imaging of cardiac allograft vasculopathy", JACC Cardiovasc Imaging, 6, pp.613~623 (2013)
- Eisen HJ, "Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients", N Engl J Med, 349, pp.847~858 (2003)
- Mancini D, "Use of rapamycin slows progression of cardiac transplantation vasculopathy", Circulation, 108, pp.48~53 (2003)
- Gonzalez-Vilchez F, "Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation", J Heart Lung Transplant, 31, pp.288~295 (2012)
- Radovancevic B, "Retransplantation in 7, 290 primary transplant patients : a 10-year multi-institutional study", J Heart Lung Transplant, 22, pp.862~868 (2003)
- Goerler H, "Cardiac retransplantation : is it justified in times of critical donor organ shortage? Long-term single-center experience", Eur J Cardiothorac Surg, 34, pp.1185~1190 (2008)